Cargando…
Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report
BACKGROUND: Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment. CASE PRESENTATION: We report here on the case of a patient presenting with hypersensitivity pneumonitis while being treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor. CO...
Autores principales: | Sibertin-Blanc, Camille, Norguet, Emmanuelle, Duluc, Muriel, Louis, Guillaume, Seitz, Jean-François, Dahan, Laetitia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843542/ https://www.ncbi.nlm.nih.gov/pubmed/24245774 http://dx.doi.org/10.1186/1756-0500-6-471 |
Ejemplares similares
-
T-bet controls severity of hypersensitivity pneumonitis
por: Abdelsamed, Hossam Aly, et al.
Publicado: (2011) -
Hypersensitivity pneumonitis
por: Lacasse, Yves, et al.
Publicado: (2006) -
Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019) -
Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022) -
Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis
por: Yamashita, Masahiro, et al.
Publicado: (2015)